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Edited by Miguel De la RosaAbstract A peptide constrained to a conformation of second
extracellular loop of human prostaglandin-E2 (PGE2) receptor
subtype3 (hEP3) was synthesized. The contacts between the pep-
tide residues at S211 and R214, and PGE2 were ﬁrst identiﬁed
by NMR spectroscopy. The results were used as a guide for
site-directed mutagenesis of the hEP3 protein. The S211L and
R214L mutants expressed in HEK293 cells lost binding to
[3H]PGE2. This study found that the non-conserved S211 and
R214 of the hEP3 are involved in PGE2 recognition, and implied
that the corresponding residues in other subtype receptors could
be important to distinguish the diﬀerent conﬁgurations of PGE2
ligand recognition sites.
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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receptor1. Introduction
Prostaglandin (PG) E2 exerts its actions by acting on a group
of G-protein-coupled receptors (GPCRs) which are designated
as subtypes EP1, EP2, EP3 and EP4. These EPs exhibit diﬀer-
ences in signal transduction and tissue localization [1–3] and
yet share common ligands. For example, the EP3 mediates
the pyrogenic response [4], EP1 and EP3 mediate release of
corticotropin-releasing hormone [5], EP2 facilitates ovulation
and fertilization [6] and EP2 and EP4 mediate collagen-in-
duced arthritis. Also, prostanoids exert both pro-inﬂammatory
and anti-inﬂammatory responses, through regulation of gene
expression in relevant tissues [7].
The agonists to EP induce a signaling cascade inside the cell
which seems to have diﬀerences and similarities and yet show
diﬀerent signaling outcomes. EP1 mediate signaling by activa-
tion of phospholipase C, protein kinase Ca and c-Src with
upregulation of endothelial growth factor-C [8]. The EP2
and EP4 are linked to cAMP/protein kinase A and phosphoin-Abbreviations: NOESY, nuclear overhauser eﬀect spectroscopy; TOC-
SY, total correlation spectroscopy; NOE, nuclear overhauser eﬀect
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multiple G proteins such as the Gi, resulting in the inhibition
of adenylyl cyclase and Gs resulting in cAMP production
[10,11]. EP3 can also activate the Ras signaling pathway lead-
ing to cancers [12].
The seven conserved residues in the second extracellular
loop (eLP2) of rabbit EP3 involved in ligand recognition has
been demonstrated previously [13]. However, in this paper
we hypothesize that the diﬀerences in ligand recognition and
ultimately the functional eﬀect must logically lie in the non-
conserved region as these EPs have multiple common ligands
showing diﬀerent eﬀects. For example, PGE2 acts as an inﬂam-
matory molecule, whereas PGE1 acts as an anti-inﬂammatory
molecule and both act on the same set of EPs with diﬀerent
aﬃnities [14]. Thus, in order to understand the EPs it is impor-
tant to uncover how the eight prostanoid receptors can distin-
guish between the similar prostanoids, which are synthesized
from the same precursor, PGH2. Using the TM (transmem-
brane) domains of the working model for the EP3 receptor
the constrained peptide mimicking the EP3 eLP2 was synthe-
sized and puriﬁed. The residues in the EP3 eLP2 interacting
with PGE2 in solution were determined by NMR spectros-
copy. The importance of this study lies in the fact that it helps
us recognize the fundamental diﬀerences that give quality to a
receptor and can be used for future beneﬁt of therapeutics.2. Materials and methods
D2O (Cambridge Isotope Laboratories, Andover, MA), PGE2
(Amersham Biosciences, Piscataway, NJ), HEK293 cells (ATCC,
Manassas, VA), DMEM culture media (Invitrogen, Carlsbad, CA),
and [3H]PGE2 and PGE2 (Perkin–Elmer, USA).
2.1. Peptide synthesis and puriﬁcation
A peptide mimicking the human EP3 eLP2 (residues 189–227,
Fig. 1B) with homocysteine added at both ends was synthesized using
the solid phase method [15,16]. After cleavage with TFA, the peptide
was puriﬁed by HPLC on a C4 reversed phase column with a gradient
from 0% to 80% acetonitrile in 0.1% TFA. For cyclization, the puriﬁed
peptide (0.02 mg/ml) was dissolved in H2O and adjusted to pH 8.5
using triethylamine, and then stirred overnight at room temperature.
It was then lyophilized and puriﬁed by HPLC on the C4 column
[17].
2.2. Fluorescence spectroscopic studies
0.75 ml (0.1 mg/ml) of the peptide was dissolved in 0.01 M phos-
phate buﬀer, pH 7.2, with 0.1 M NaCl and then incubated with various
concentrations of PGE2. Fluorescence spectra were acquired with an
Hitachi F-4500 spectroﬂuorometer using 294 nm for excitation and
300–360 nm for emission [18].European Biochemical Societies.
Fig. 1. (A) The homology model of the human EP3 receptor using
crystal structure of b2 receptor [23]. The distance in angstroms (A˚)
between the transmembrane domains are shown. The synthesized
peptide, EP3 eLP2, is marked with a circle. (B) The synthesized eLP2 in
its constrained form. (C) Structure of PGE2.
Fig. 2. Sequence alignment of eLP2s of prostanoid receptors. The
conserved residues are highlighted. Arrows indicate residues for
mutation (non-conserved region).
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and constrained peptide was dissolved in 0.5 ml, pH 5.5, 10 mM so-
dium phosphate buﬀer with 10% D2O, pH 6.0, at a ﬁnal concentration
of 2.43 mM. 0.5 mg of PGE2 was dissolved in 50 ll ethanol-d6 and then
added to 0.45 ml of sodium phosphate buﬀer (20 mM) containing 10%
D2O [17].
2.3. NMR experiments
NMR was performed on a Bruker AVANCE 800 MHz NMR spec-
trometer at 293 K. 2D Nuclear overhauser eﬀect spectroscopy
(NOESY) (300 ms mixing time), total correlation spectroscopy (TOC-
SY) and double quantum ﬁltered-correlation spectroscopy for above
samples were recorded. Thereafter, 2.5, 5, 10, 20 and 40 ll of PGE2
in ethanol-d6 solution (1 mg/100 ll) was added into the sample and
the 1D proton spectra were recorded. 2D NOESY (200 ms mixing
time) and TOCSY spectra were then recorded for the ﬁnal mixture
of EP3 eLP2 and PGE2. Details are mentioned in previous publications
[18,21].
2.3.1. Site-directed mutagenesis. pAcSG-EP3 wild-type cDNA was
ﬁrst subcloned into EcoRI/XbaI sites of pcDNA3.1(+) expression vec-
tor. The EP3 receptor mutants were then constructed using standard
PCR. Details in [22]. The plasmids were prepared using Midiprep kit
(Qiagen) for transfection into HEK293 cells.
2.3.2. Expression of EP3 receptor wild-type and mutants in HEK293
cells. HEK293 cells were transfected with puriﬁed cDNA of
pcDNA3.1(+)/EP3 wild-type and mutants with lipofectamine accord-ing to the manufacturers instructions [22]. Western blot was per-
formed to evaluate the protein expression (Fig. 8A).
2.3.3. Ligand binding assay. Ligand binding assay for the WT and
mutant EP3 receptor was performed on whole cells in 48-well culture
plates with 0.035 and 1 nM [3H]PGE2, respectively, in the presence
and absence of 5 lM unlabeled (cold) PGE2 in the 0.1-ml reaction vol-
ume of DMEM at room temperature for 60 min. The reaction was ter-
minated by adding 1 ml of ice-cold washing buﬀer (25 mM Tris–HCl,
pH 7.4). The ligand bound cells were dissolved in 0.5 N NaOH, which
was later, neutralized with acetic acid. The procedure was modiﬁed
from Ref. [20] and radioactivity detected by MicroBetaTrilux counter.3. Results
3.1. Homology model and peptide design
The human EP3 receptor model with seven TM domains
was created by homology modeling using the crystallized beta2
receptor as the template [23]. The distance between the trans-
membrane helices was 12–14 A˚ which is similar to the distance
between the disulphide bonds formed by the homocysteine res-
idues in the constrained peptide (approximately 12 A˚) (Fig. 1A
and B).
3.2. Sequence alignment of the eLP2 regions from the eight
human prostanoid receptors
The identical residues, QW-PGTWCF, in the eLP2 regions
are centrally located within the eLP2.The identiﬁed residues,
S211 and R214 are not conserved in other prostanoid receptor
eLP2s indicating that these residues of EP3 eLP2 could be in-
volved in speciﬁc ligand recognition (Fig. 2).
3.3. Fluorescence spectroscopy of PGE2 with the peptide
segment
The recorded intrinsic ﬂuorescence signal was generated
from the Trp residue, which is sensitive to the conformational
change in the peptide induced by the interaction with its li-
gand. The ﬂuorescence intensity of the constrained peptide in-
creased by 11–14% (Kd 5.12) with PGE2, which started at
3.4 lM and became saturated at 68.1 lM of the ligand
(Fig. 3). However, no signiﬁcant ﬂuorescence changes were in-
duced upon the addition of PGE2 to the crude EP3 eLP2.
These results indicate that the constrained EP3 eLP2 peptide
Fig. 3. Fluorescence spectroscopic of PGE2 with the synthetic peptide
(constrained and crude). The ﬂuorescence enhancement of the
synthetic constrained peptide (0.1 mg/ml, squares, Kd 5.12) by the
addition of its ligand (3.4–68.1 lM) was plotted. The non-signiﬁcant
ﬂuorescence changes of the non-cyclised EP3 eLP2 peptide (0.1 mg/ml,
circles) is also plotted.
Fig. 4. NOESY spectra. (A) The cross-peaks (in rectangles) of PGE2
shown as negative (green) phases (fast tumbling rate), compared to the
diagonal. (B) The cross-peaks of PGE2 interacted with EP3 eLP2
peptide are shown as the positive phase (blue phases), (slow tumbling
rate). Peaks indicate extra intra-molecule NOEs of the PGE2 interac-
tion with EP3 eLP2.
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eLP2 of the EP3 receptor.
3.4. 2D 1H NMR spectroscopy of PGE2 with the peptide
segment
To further identify which proton in PGE2 contacts the EP3
eLP2 fragment, 2D proton NMR spectroscopy was used.
NOESY, TOCSY of PGE2 (in the absence and presence of
the constrained EP3 eLP2 peptide) were recorded in H2O with
10% D2O. The resonance assignment of PGE2 is summarized
in Table 1. The binding of PGE2 to the peptide was supported
by the changes in the proton cross-peaks, from the negative
phase (green peaks, fast tumbling) in free PGE2 (Fig. 4A) to
the positive phase (blue peaks, slow tumbling) in PGE2 with
the EP3 eLP2 peptide (Fig. 4B). This is a strong indication
of the transition of PGE2 from free to bound status. By anal-Table 1
Proton chemical shift of PGE2 in the absence and presence of EP3
eLP2
In the absence of EP3 eLP2 In the presence of EP3 eLP2
H2 2.081 2.223
H3 1.397 1.507
H4 1.818 1.941
H5 5.248 5.356
H6 5.085 5.210
H7 2.086 2.188
H8 2.145 2.235
H10b 2.566 2.698
H10a 1.975 2.094
H11 3.945 4.048
H12 2.238 2.329
H13 5.377 5.485
H14 5.377 5.485
H15 3.910 4.024
H16 1.291 1.478
H17 1.245 1.478
H18 1.058 1.372
H19 1.034 1.167
H20 0.608 0.733ysis, more cross-peaks appeared in the NOESY spectrum of
PGE2 with the eLP2 peptide, which clearly indicates that a sta-
ble conformation of PGE2 was induced by the peptide.
3.5. Identiﬁcation of residues for point mutation
From the NOESY spectra, intermolecular cross-peaks were
identiﬁed for two residues [serine (S211) and arginine (R214)]
which indicated a close contact between these two residues
and PGE2. Figs. 5–7 show the intermolecular nuclear overha-
user eﬀect (NOE) cross-peaks. The beta proton of S211 was
shown to contact with H7 of PGE2, and the guanidine hydro-
gens of residue R214, was shown to come in contact with pro-
tons, H2, H4, and H13/14 of PGE2 in solution. Residue
asparagine (N217) was chosen as an internal control due to
its similarity in size and hydrophilicity. The identiﬁed residues
were mutated to leucine (L) which is more hydrophobic in nat-
ure.
3.6. Radioligand binding of EP3 wild-type versus mutants
The mutants S211L and R214L showed signiﬁcantly reduced
binding when compared to the EP3 wild-type and the mutant,
N217L (internal control). Cold PGE2 inhibited the [
3H]PGE2
binding which was similar to that of HEK293 cells only. On
comparing the [3H]PGE2 binding at low concentration
(0.035 nM, 9000 cpm) and high concentrations (0.1185 nM,
30000 cpm) we realized that there was an increase in
[3H]PGE2 binding to the mutants, although still signiﬁcantly
less compared to wild-type and internal control (Fig. 8B and
C). This signiﬁes that a single point mutation can signiﬁcantly
alter the receptor binding and that the binding is not restored
even with high concentration.4. Discussion
Based on our molecular modeling studies, the TP receptor
ligand, SQ29,548, must contact the extracellular domains of
the receptor before binding to the residues on the third and
Fig. 5. (I) TOCSY spectrum of PGE2. (II) NOESY spectra of EP3
eLP2 peptide, (IIA) serine 211 and (IIB) arginine 214 cross-peaks. (III)
The mixture of EP3 eLP2 peptide and PGE2, (IIIA) serine 211 with
PGE2 and (IIIB) arginine 214 with PGE2 cross-peaks.
Fig. 7. (A) Magniﬁed cross-peaks (Fig. 5IIB) for arginine 214 of the
eLP2 peptide. (B) Magniﬁed cross-peaks (Fig. 5IIIB) for arginine 214
guanidine protons (dimension 1) in contact with proton 2, 4 and 13/14
of PGE2 (dimension 2). (C) Chemical structure representation.
Fig. 6. (A) Magniﬁed cross-peaks for serine 211 from Fig. 5IIA. (B)
Magniﬁed cross-peaks (Fig. 5IIIA) of peptide with PGE2 for residue
serine 211 b proton (dimension 1) in contact with proton 7 of PGE2
(dimension 2). (C) Chemical structure representation.
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contact residues on the molecular surface are also speciﬁc
[22]. Also the constrained eLP2 peptide of the TP receptor
changes its conformation upon the addition of the receptor
antagonist (SQ29,548) [18]. Studies have provided evidence
to support the hypothesis of the second extracellular loops
involvement in ligand recognition [20,21] and that point muta-
tions of several cysteine residues at these loops reduce binding
activity [19]. Site-directed mutagenesis of seven conserved res-
idues (198–205) clustered in the amino portion of the rabbit
EP3 eLP2 has been performed and their ligand binding proﬁles
assessed, in transfected HEK293 cells [13,20,22].We chose the EP3 receptor for its unique ability to couple to
multiple G proteins such as the Gi subunits (adenylyl cyclase
inhibition) and Gs subunit (cAMP stimulation) [10,11]. We
hypothesize that this selection of G proteins is likely to be li-
gand-dependent.
The residues identiﬁed by us for ligand recognition (S211 &
R214) are chieﬂy located in the non-conserved region of the
eLP2. This means that the conserved regions, though impor-
tant for ligand recognition, may not be as important as the
non-conserved region in deﬁning the receptors choice of signal
transduction. The diﬀerences observed in the function of the
receptors sharing a common ligand could in fact be due to
the conformational changes brought about by these non-con-
served residues which lead to the diversiﬁcation of the signal
transduction. The X-ray crystal structure for a majority of
mammalian GPCRs is not yet available therefore the ﬁrst step
to identify the structural basis of the ligand-speciﬁc recognition
of the extracellular parts is the understanding of the residues
involved.
In this paper, we localized the residues within the eLP2 re-
gion responsible for the ligand recognition, using two-dimen-
sional NMR spectroscopy. The residues identiﬁed (S211 &
Fig. 8. (A) Western blot of wild-type and mutant EP3 receptors on
HEK293 cells. (1) HEK293 cells, (2) wild-type EP3 (3) Mutant S211L,
(4) R214L, and (5) N217L. (B) Histograms showing total (black bars)
and non-speciﬁc binding (white bars). There is a signiﬁcant decrease in
binding for the mutants with low [3H]PGE2 counts (0.035 nM,
9000 cpm). (C) Shows increased binding for mutants at higher counts
(0.1185 nM, 30000 cpm) though still signiﬁcantly less than the wild-
type and the internal control N217L. Binding to HEK293 cells was
comparable to non-speciﬁc binding in the presence of cold PGE2
(5 lM, in both B and C). The reaction volume was 100 ll, with
approximately 0.05 million cells/well. The results are presented as
mean ± S.D. with (n = 3).
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approach for the native EP3 receptor. The radioligand
([3H]PGE2) binding further supports our hypothesis that the
point mutation in the second extracellular loop of the receptors
greatly decreases the binding (Fig. 8). Our next step will be to
use this data from the combination of the NMR experiments
and mutagenesis to give detailed structural information about
the interaction of the receptor and ligand, which cannot be
achieved by other approaches such as general mutation ap-
proach, photoaﬃnity labeling, and site-speciﬁc antibody
screening. This approach can be used to characterize the ligand
binding to other domains of the receptor as well.
The key factor in this study was to design a synthetic peptide
with biological function. By using a constrained peptide, we
successfully identiﬁed the ligand recognition site for the recep-
tor. The identiﬁcation of the residues in the EP3 eLP2 is theﬁrst step in solving the ligand-recognition pocket. We suspect
that the ligand-recognition site might diﬀer from the ﬁnal li-
gand-binding site, as we have shown with the TP receptor.
Though the ligand binding site located within the transmem-
brane domain is conserved, the initial docking residues of the
prostanoid receptors are ligand speciﬁc [22]. In conclusion,
our proton-level information for identiﬁcation of the EP3
receptor ligand-recognition site on the extracellular domain
will serve as a valuable tool to characterize the structure of
the ligand-docking site and understand the variations in signal-
ing outcomes. In addition, it will also provide reference infor-
mation on speciﬁc recognition diﬀerences and predictions of
ligand-docking sites for other prostanoid receptors.
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